TP53 and lung carcinoma: Cellular senescence inhibits tumor progression in vivo, thus making it an attractive therapeutic target for cancer.10 The drug concentration of anticancer agents or the dose of radiation required to induce senescence is lower than that necessary to kill cells; therefore, senescence-inducing treatments provide the advantage of enhancing treatment efficacy and reducing side effects in anticancer therapy.9 In this study, we demonstrated a novel anticancer effect of PT through senescence induction, which was preferentially observed in p53+ lung cancer cells.